| | |
| Dow, S&P 500 slip as second quarter nears close Friday, Jun 28, 2013 12:19 PM PDT | Top |
| Rio Tinto wins end to human rights abuse lawsuit in U.S. Friday, Jun 28, 2013 11:51 AM PDT | Top |
| Professor who found oldest U.S. cave art says there's more Friday, Jun 28, 2013 10:27 AM PDT | Top |
| Sticker-shock derails opportunistic U.S. loan deals, for now Friday, Jun 28, 2013 09:45 AM PDT By Lynn Adler and Leela Parker (Reuters) - Market turbulence has prompted U.S. companies to shelve more than $14 billion in loans meant to slice borrowing costs or fund shareholder dividends, confining most issuance to borrowers with imminent financing needs. At least 15 of these opportunistic deals have been pulled since late-May, with more withdrawals likely, while issuers that have opted to forge ahead with their deals have been forced to sweeten terms to lure investors. ... Full Story | Top |
| OPEC pumps less oil in June on Africa setbacks: Reuters survey Friday, Jun 28, 2013 09:15 AM PDT | Top |
| Accenture cuts full-year outlook as consulting slows further Friday, Jun 28, 2013 08:41 AM PDT | Top |
| Regulators pave way for biosimilar drug breakthrough Friday, Jun 28, 2013 08:35 AM PDT LONDON/ZURICH (Reuters) - European regulators have cleared the way for the first serious threat to the makers of multibillion-dollar biotechnology drugs to treat diseases such as cancer and rheumatoid arthritis. The European Medicines Agency (EMA) said on Friday that its experts had backed approval of two copycat versions of Johnson & Johnson and Merck & Co's blockbuster rheumatoid arthritis drug Remicade - the first time a green light has been given for such antibody-based medicines. ... Full Story | Top |
| Regulators pave way for dissimilar drug breakthrough Friday, Jun 28, 2013 08:34 AM PDT LONDON/ZURICH (Reuters) - European regulators have cleared the way for the first serious threat to the makers of multibillion-dollar biotechnology drugs to treat diseases such as cancer and rheumatoid arthritis. The European Medicines Agency (EMA) said on Friday that its experts had backed approval of two copycat versions of Johnson & Johnson and Merck & Co's blockbuster rheumatoid arthritis drug Remicade - the first time a green light has been given for such antibody-based medicines. ... Full Story | Top |
| Monsanto unapproved GMO wheat stored in Colorado through '11 Friday, Jun 28, 2013 08:17 AM PDT By Carey Gillam (Reuters) - Monsanto Co's unapproved, experimental genetically engineered wheat, which is feared to have potentially contaminated U.S. wheat supplies after it was found growing in an Oregon field this spring, was kept in a U.S. government storage facility until at least late 2011, according to documents obtained by Reuters. The revelation that the seed for the controversial genetically engineered wheat was kept viable in a Colorado storage facility as recently as a year and a half ago comes as the U.S. ... Full Story | Top |
| Russia criticizes groups setting conditions for Syria talks Friday, Jun 28, 2013 07:01 AM PDT | Top |
| Insight: From remote Mauritania, hacker fights for Islam worldwide Friday, Jun 28, 2013 06:46 AM PDT | Top |
| Gazprom says RWE court decision won't bring additional pressure Friday, Jun 28, 2013 06:28 AM PDT MOSCOW (Reuters) - Gazprom will not face additional pricing pressure from clients in Europe after an arbitration court decision forcing Gazprom to charge a key European customer, RWE , market prices for the gas it sells, the Russian company's CEO said on Friday. European clients have lost billions of dollars in recent years due to a gap between Gazprom's prices, which are largely linked to costlier oil, and the spot markets for gas which guide the prices they can charge their own customers. ... Full Story | Top |
| Obama's environmental nominee in jeopardy from Senate Republicans Friday, Jun 28, 2013 06:20 AM PDT | Top |
| Argentine approach on YPF settlement sets floor for deal Friday, Jun 28, 2013 06:20 AM PDT | Top |
| Sanofi's MS drugs get double boost in Europe Friday, Jun 28, 2013 06:05 AM PDT LONDON (Reuters) - Sanofi's hopes in the multiple sclerosis market received a double boost on Friday as the European regulator backed an injectable treatment and adopted a more positive stance toward a pill for the neurodegenerative disease. The European Medicines Agency said it was recommending Lemtrada, Sanofi's biggest MS drug hope, for relapsing-remitting MS, ending a quarter-century development saga for the injectable treatment. ... Full Story | Top |
|

No comments:
Post a Comment